Capricor Therapeutics(US:CAPR) Benzinga·2025-11-24 20:01Core Insights - Whales have adopted a bullish stance on Capricor Therapeutics, with 61% of trades being bullish and 23% bearish [1] - The expected price movement for Capricor Therapeutics is projected between $1.0 and $10.0 [2] - The average open interest for options stands at 8,498.25, with a total volume of 54,025.00 in the last 30 days [3] Options Activity - Significant options activity includes 13 trades, with a total of 7 puts amounting to $498,769 and 6 calls totaling $468,675 [1] - The largest spotted options include a bullish put sweep with a total trade price of $146.9K and a strike price of $2.50 [6] - A bullish call trade was noted with a total trade price of $115.0K and a strike price of $10.00 [6] Company Overview - Capricor Therapeutics is a clinical-stage biotechnology company focused on developing cell and exosome-based therapeutics for Duchenne muscular dystrophy (DMD) and other diseases [7] - The company's product pipeline includes CAP-1002 and deramiocel, with deramiocel currently in Phase 3 clinical development for DMD [7] Market Status - An industry analyst has set an average target price of $13.0 for Capricor Therapeutics [8] - Roth Capital maintains a Buy rating on the stock, also targeting a price of $13 [9] - The current stock price is $5.6, reflecting a decrease of -2.61% [11]